Detalhe da pesquisa
1.
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
N Engl J Med
; 389(22): 2063-2075, 2023 Nov 30.
Artigo
Inglês
| MEDLINE | ID: mdl-37861218
2.
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
N Engl J Med
; 389(18): 1672-1684, 2023 Nov 02.
Artigo
Inglês
| MEDLINE | ID: mdl-37870974
3.
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lancet
; 402(10400): 451-463, 2023 08 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37423228
4.
Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
Tumour Biol
; 46(s1): S177-S190, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-37545290
5.
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI.
Future Oncol
; 20(15): 969-980, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38095056
6.
Real-world data for precision cancer medicine-A European perspective.
Genes Chromosomes Cancer
; 62(9): 557-563, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36852573
7.
Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma.
Br J Cancer
; 129(1): 112-121, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37120670
8.
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC.
Future Oncol
; 19(21): 1461-1472, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37249038
9.
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Future Oncol
; 19(19): 1319-1329, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-37212796
10.
[TTF-1-negative lung adenocarcinoma: special features of systemic treatment]. / Besonderheiten in der Therapie des TTF-1-negativen Adenokarzinoms der Lunge.
Pneumologie
; 77(7): 426-429, 2023 Jul.
Artigo
Alemão
| MEDLINE | ID: mdl-37094793
11.
[Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer - Interdisciplinary Guideline of the German Respiratory Society and the German Cancer Society - Abridged Version]. / Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms.
Pneumologie
; 77(10): 671-813, 2023 Oct.
Artigo
Alemão
| MEDLINE | ID: mdl-37884003
12.
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply.
N Engl J Med
; 390(3): 287-288, 2024 Jan 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38231635
13.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 381(21): 2020-2031, 2019 11 21.
Artigo
Inglês
| MEDLINE | ID: mdl-31562796
14.
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.
Cancer Immunol Immunother
; 71(2): 251-265, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-34125345
15.
Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians.
Respiration
; 101(3): 307-320, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35231915
16.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(2): 198-211, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33476593
17.
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
N Engl J Med
; 379(23): 2220-2229, 2018 12 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30280641
18.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med
; 378(24): 2288-2301, 2018 Jun 14.
Artigo
Inglês
| MEDLINE | ID: mdl-29863955
19.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
N Engl J Med
; 378(22): 2093-2104, 2018 May 31.
Artigo
Inglês
| MEDLINE | ID: mdl-29658845
20.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med
; 379(24): 2342-2350, 2018 12 13.
Artigo
Inglês
| MEDLINE | ID: mdl-30280658